Cargando…
α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
BACKGROUND AND AIMS: Ulcerative colitis (UC) is a superficial diffuse inflammation restricted to the colon and rectum. Inflammation within the small bowel may occur several years after a pancolectomy. The pathogenesis is unknown and seems to be different from Crohn's disease or other causes of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501135/ https://www.ncbi.nlm.nih.gov/pubmed/31143480 http://dx.doi.org/10.1155/2019/2091089 |
_version_ | 1783416059505672192 |
---|---|
author | Filip, Rafał Goliat, Błażej Dziechciaż, Małgorzata Dąbrowski, Piotr Osuchowski, Michał Paluszkiewicz, Piotr |
author_facet | Filip, Rafał Goliat, Błażej Dziechciaż, Małgorzata Dąbrowski, Piotr Osuchowski, Michał Paluszkiewicz, Piotr |
author_sort | Filip, Rafał |
collection | PubMed |
description | BACKGROUND AND AIMS: Ulcerative colitis (UC) is a superficial diffuse inflammation restricted to the colon and rectum. Inflammation within the small bowel may occur several years after a pancolectomy. The pathogenesis is unknown and seems to be different from Crohn's disease or other causes of diseases of the small intestine, but an association with colectomy due to UC is very likely. METHODS AND RESULTS: We describe the case of a patient with a probable diagnosis of pan-UC accompanied by Sjögren's syndrome and partial IgA deficiency, who developed enteritis after a restorative pancolectomy. For induction and maintenance of remission, the patient was successfully treated with mycofenolate mofetil (MMF) and vedolizumab (VDZ). CONCLUSIONS: We suggest that a previously refractory to standard therapy UC-related enteritis can be treated with combination MMF and VDZ. |
format | Online Article Text |
id | pubmed-6501135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-65011352019-05-29 α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis Filip, Rafał Goliat, Błażej Dziechciaż, Małgorzata Dąbrowski, Piotr Osuchowski, Michał Paluszkiewicz, Piotr Case Rep Gastrointest Med Case Report BACKGROUND AND AIMS: Ulcerative colitis (UC) is a superficial diffuse inflammation restricted to the colon and rectum. Inflammation within the small bowel may occur several years after a pancolectomy. The pathogenesis is unknown and seems to be different from Crohn's disease or other causes of diseases of the small intestine, but an association with colectomy due to UC is very likely. METHODS AND RESULTS: We describe the case of a patient with a probable diagnosis of pan-UC accompanied by Sjögren's syndrome and partial IgA deficiency, who developed enteritis after a restorative pancolectomy. For induction and maintenance of remission, the patient was successfully treated with mycofenolate mofetil (MMF) and vedolizumab (VDZ). CONCLUSIONS: We suggest that a previously refractory to standard therapy UC-related enteritis can be treated with combination MMF and VDZ. Hindawi 2019-04-22 /pmc/articles/PMC6501135/ /pubmed/31143480 http://dx.doi.org/10.1155/2019/2091089 Text en Copyright © 2019 Rafał Filip et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Filip, Rafał Goliat, Błażej Dziechciaż, Małgorzata Dąbrowski, Piotr Osuchowski, Michał Paluszkiewicz, Piotr α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis |
title |
α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis |
title_full |
α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis |
title_fullStr |
α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis |
title_full_unstemmed |
α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis |
title_short |
α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis |
title_sort | α4β7 integrin antagonist vedolizumab for the treatment of refractory ileitis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501135/ https://www.ncbi.nlm.nih.gov/pubmed/31143480 http://dx.doi.org/10.1155/2019/2091089 |
work_keys_str_mv | AT filiprafał a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis AT goliatbłazej a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis AT dziechciazmałgorzata a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis AT dabrowskipiotr a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis AT osuchowskimichał a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis AT paluszkiewiczpiotr a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis |